ADDERALL 20 Drug Patent Profile

When do Adderall 20 patents expire, and what generic alternatives are available?

Adderall 20 is a drug marketed by Teva Womens and is included in one NDA.

The generic ingredient in ADDERALL 20 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for ADDERALL 20

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	11
DailyMed Link:	ADDERALL 20 at DailyMed

Recent Clinical Trials for ADDERALL 20

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gagan Joshi	PHASE4
Massachusetts Institute of Technology (MIT)	PHASE4
Boston Children's Hospital	Phase 1

See all ADDERALL 20 clinical trials

US Patents and Regulatory Information for ADDERALL 20

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Womens	ADDERALL 20	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	011522-008	Feb 13, 1996		DISCN	Yes	No

International Patents for ADDERALL 20

See the table below for patents covering ADDERALL 20 around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2003504406
Australia	6089200
European Patent Office	1202739

Market Dynamics and Financial Trajectory for Adderall 20 mg

Last updated: February 20, 2026

What is the current market landscape for Adderall 20 mg?

Adderall 20 mg is a central nervous system stimulant primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. The drug's active ingredients are mixed amphetamine salts, including amphetamine and dextroamphetamine. The medication is available via prescription and faces controlled substance regulation due to its potential for abuse.

The global ADHD pharmacotherapy market was valued at approximately $18 billion in 2022, with stimulant medications like Adderall constituting roughly 55% of this share[1]. The U.S. accounts for over 70% of prescriptions, driven by high ADHD diagnosis rates and healthcare access.

How do market trends influence Adderall 20 mg?

Prescription Trends: U.S. prescriptions of stimulant medications grew by over 8% annually from 2018 to 2022[2]. This increase correlates with rising awareness, diagnosis rates, and ongoing clinical studies. However, recent policy shifts, including tighter regulations and increased monitoring, aim to reduce misuse, impacting prescription volume growth.

Regulatory Environment: The Drug Enforcement Agency (DEA) classifies Adderall as a Schedule II controlled substance. Recent proposals to reschedule stimulants to a more restrictive category could impact supply chains and prescribing behavior.

Competition: Modified-release formulations (e.g., Vyvanse, Concerta) and non-stimulant alternatives (e.g., atomoxetine) present competitive considerations. The rise of generic versions reduces costs and pressure on branded sales.

Patient Demographics: ADHD diagnoses are expanding among adult populations, broadening the market beyond children and adolescents. This demographic shift sustains ongoing demand and influences dosage forms and strengths.

What are the key factors influencing Adderall 20 mg’s financial trajectory?

Patent and Manufacturing Status

Adderall 20 mg is available as a generic drug. Its patent expired in 2018[3], opening the market to multiple generic manufacturers. This proliferation led to significant price erosion, with average prices decreasing by approximately 21% annually post-generic entry[4].

Pricing and Reimbursement

Average wholesale prices (AWP) for 30-count Adderall 20 mg tablets declined from about $250 in 2018 to approximately $150 in 2022[5]. Insurance reimbursement policies increasingly favor cost-effective generics, further reducing revenue for branded formulations.

R&D Investment and Pipeline

No new formulations or enhanced delivery systems for Adderall 20 mg are currently under development by major pharmaceutical companies. Most R&D efforts focus on non-stimulant formulations and digital therapeutics.

Manufacturing and Supply Chain

The supply chain has stabilized after initial disruptions during the COVID-19 pandemic. Producing active pharmaceutical ingredient (API) remains concentrated in limited geographies, mainly India and China, exposing risks of geopolitical or trade issues.

Revenue Projections

For major branded producers (e.g., Shire, now part of Takeda), branded sales of Adderall shrank from over $2 billion in 2018 to below $1 billion in 2022, mainly due to generic competition. Industry estimates project that overall U.S. stimulant ADHD medication revenues will decline mildly to stabilize, but the segment remains sizable due to consistent demand.

How do regulatory and societal factors influence market and financial outlooks?

Political initiatives to combat misuse have led to stricter prescription monitoring programs (PDMPs), which can constrain rapid prescription increases. Conversely, increased awareness about ADHD fosters sustained demand.

States' legislative measures, such as limits on prescription quantities, influence dispensing volume but do not significantly curb overall market size.

What future scenarios could shape Adderall 20 mg's financial profile?

Scenario	Impact on Market and Revenue	Likelihood
Tightened regulation	Reduced prescription volume, pressure on prices	Medium
Emergence of non-stimulant meds	Shift in market share toward non-stimulant treatments	High
Digital therapeutics adoption	Potential to replace or supplement pharmacotherapy, reducing drug sales	Medium
Supply chain disruptions	Cost increases or availability issues, impacting profitability	Low to Medium

Key Takeaways

• The Adderall 20 mg market is stabilizing post-generic entry, with declining prices and revenue.
• Prescription volume growth faces regulatory constraints and societal concerns over misuse.
• No significant new developments are announced, limiting revenue expansion.
• Competition from non-stimulant medications and digital therapies is rising.
• Supply chain dependencies in manufacturing pose long-term risks.

FAQs

1. What is the main driver of Adderall 20 mg sales?
Prescription volume in the U.S., driven by ADHD diagnosis rates and healthcare access.

2. How has generic competition affected pricing?
Prices have decreased approximately 21% annually since patent expiration, cutting revenue margins.

3. Are there any new formulations of Adderall in development?
No; current focus is on market maintenance, with development efforts directed toward alternative therapies.

4. How might regulation changes impact the market?
Stricter policies could reduce prescription rates, impacting sales volume but also potentially decreasing misuse concerns.

5. What is the outlook for the long-term financial performance of Adderall 20 mg?
Primarily stable but declining; continued generic competition and societal shifts favor non-stimulant therapies.

---

References

[1] IQVIA. (2022). Market Overview of ADHD Medications.
[2] CDC. (2022). ADHD Diagnosis and Prescription Trends.
[3] U.S. Patent and Trademark Office. (2018). Patent expiration for Adderall.
[4] SSR Health. (2022). Drug Price Trends Post-Generic Entry.
[5] MMIT. (2022). Wholesale Price Analysis of ADHD Medications.